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Conventional spectrophotometric methods may be easily affected by the presence of interferences in complex mixtures, such as 
pharmaceutical formulations containing nanoparticules. Therefore requiring prior treatment or extraction of the analyte, and not 
always providing an adequate response. Derivative spectrophotometry methods (2D) aim to eliminate those interferences – 
establishing alternative methods for drug determination in complex matrices. This work investigated the application of derivate 
spectrophotometry to assess simvastatin in polymeric nanocapsules (SIVNC). Shimadzu® UV-1650 double-beam 
spectrophotometer with 1.0 cm quartz cells was used in this study. The second-order derivative spectrum was obtained employing 
Δλ=20,000 nm and scaling factor=9.0. The determinations were performed at 239 nm (2D239) by the zero-crossing method. 2D239 
method was validated according to the parameters: specificity, linearity, robustness, precision, and accuracy. Results: The 
specificity test showed that there was no interference of non active ingredients to the analysis of SIVNC formulation in 2D239. The 
standard curve showed a correlation coefficient of 0.994. The robustness was evaluated by small changes in the conditions of 
sample analysis and no significant changes were observed. The precision was demonstrated by relative standard deviation (RSD) 
of intra-day (RSD=1.61-3.76%) and inter-day studies (RSD=2.32%). The recovery test resulted in an average of 100.66%, 
confirming the accuracy of the method. The procedure was simple and fast; therefore the 2D technique presents an alternative for 
the determination of SIVNC in the developd pharmaceutical formulation. 
 




Alzheimer's disease (AD) is a progressive and irreversible 
neurodegenerative disorder which leads to memory loss and 
severe cognitive disorders (1). It is related to the effects of 
β-amyloid protein, which may accumulate in the brain, 
causing neurotoxicity and neurodegeneration (2).  
Studies suggest that there is a pathophysiological 
relationship between β-amyloid protein and the levels of 
serum cholesterol, Thus, increased values of this protein and 
the apolipoprotein E (ApoE), responsible for the metabolism 
of cholesterol, are risk factors for AD (3). Accordingly, the 
statins drug classe may exert protective effects against AD 
and other types of dementia. Statins act through a 
cholesterol dependent mechanism, reducing the production 
of β-amyloid protein and, therefore, the risk of developing 
AD (4).  
In order to reduce the evolution of AD it is necessary for the 
drug to overcome the blood brain barrier so it can reach its 
site of action. This barrier is essential to protect the neural 
tissue and functions as a natural obstacle to the absorption of 
medicines intended to correct nerve disturbances (5). 
Lipophilic statins, such as simvastatin, may cross the blood 
brain barrier and penetrate the membranes of the cell, being 
more efficient than hydrophilic drugs for the treatment of 
dementia (6).  
Simvastatin is a white or almost white crystalline powder 
practically insoluble in water and freely soluble in alcohol. 
Its molecular weight is 418.56 g/mol and has the chemical 
name 2,2-dimethylbutyric acid, 8 -ester with (4R, 6R) -6 - [2 
- [(1S, 2S, 6S, 8S, 8aR) -1,2,6,7,8,8 a-hexahydro-8-hydroxy-
2 ,6-dimethyl -1-naphthyl] ethyl] tetrahydro-4-hydroxy-2H-
pyran-2-one (Fig. 1). Simvastatin (7) belongs to the class of 
statins, which are lipid lowering agents that inhibit the 
action of HMG-CoA (hydroxy-3-methyl-glutaryl-CoA) 
reductase, a key enzyme in cholesterol synthesis. Thus 
leading to a reduction in cholesterol blood levels and a 
consequent increase in the expression of receptors of low-
density lipoproteins (8).  
 
 
Figure 1. Chemical structure of simvastatin. 
Simvastatin is highly selective for the liver tissue after oral 
administration, it undergoes first-pass metabolism and the 
systemic exposure to the active form becomes lower than 
5%. The drug also has important side effects such as 
constipation, headache, stomach pain, and nausea (9, 10). 
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The development of nanostructured systems aims to 
minimize the loss of the active substance, to reduce the 
unwanted effects and to increase the effectiveness of 
simvastatin by directing the drug to its site of action. 
Due to this principle, suspensions of simvastatin 
nanocapsules (SIVNC) using triglycerides of capric/caprylic 
acid as oil core and poly(ε-caprolactone) as polymeric unit 
were developed. A high performance liquid chromatography 
(HPLC) method for the determination of simvastatin 
nanocapsules was developed and validated by Lorenzoni 
2019. However, according to Costa et al (2012), HPLC 
methods may demand extensive use of reagents for the 
determination of medicines, thereby generating large 
amounts of waste and becoming more dangerous for the 
environment (12, 13). Therefore, it is desirable for the 
development of fast and accurate method with reduced 
production of residues for analysis of drugs and medicines. 
This study aimed to develop and validate an analytical 
method for the quantification of simvastatin in suspensions 
containing SIVNC by derivative ultraviolet 
spectrophotometry.  
Materials and methods 
Development of nanocapsules  
The development of the SIVNC applied simvastatin 98.4% 
(Deg, Brazil), sorbitan monostearate 60 - Span® 60, (Sigma-
Aldrich, USA), triglycerides of caprylic/capric acids (Via 
Farma, Brazil), poly(ε-caprolactone) (Sigma-Aldrich, USA), 
polysorbate 80 - Tween 80® (Henrifarma, Brazil) and 
acetone PA (Nuclear, Brazil). The solvents employed were 
HPLC grade acetonitrile (JT Baker, USA) and ultrapure 
water (Millipore, USA). The active pharmaceutical 
ingredient (API) was characterized by Lorenzoni et al. 
(2019) and applied as the chemical standard for the 
quantification of simvastatin in SIVNC. 
The SIVNC were prepared by interfacial polymer 
deposition, where oil phase (poly(ε-caprolactone), sorbitan 
monostearate 60, triglycerides of capric/caprylic acid, 
acetone, and simvastatin) was poured into the aqueous phase 
(polysorbate 80 and ultrapure water) under magnetic stirring 
and moderate heating (40 ºC) for 10 minutes. The organic 
solvent was displaced and the volume of the suspension 
reduced by using a rotary evaporator (801 Fisaton) until 25 
mL, equivalent to 1 mg/ml simvastatin suspension. The 
quali/quantitative composition of the SIVNC is described in 
table 1. The blank nanocapsules (BLNC) were produced as 
described for the SIVNC, except for the absence of the 
active ingredient.  
Table 1. Composition of the suspension of nanocapsules of poly(ε-
caprolactone) with simvastatine. Volume reduced to 25 mL with a 
rotary evaporator. 
Oil Phase Aqueous Phase 
poly(ε-caprolactone)… 250 mg polysorbate 80 ........... 192 mg 
sorbitan monostearate …96 mg water ........................... 125 mL 
simvastatin .................... 25 mg  
triglycerides of caprylic/capric 
acids ……………….... 395 mg 
 
acetone ……...…….... 62.5 mL  
 
 
Physical-chemical characterization  
The characterization of parameters such as particle size and 
polydispersity index were performed by dynamic light 
scattering and zeta potential,  according to the 
electrophoretic mobility, using the Zetasizer® Nano ZS 
(Malvern, England) equipment. Samples of the suspensions 
of the BLNC and SIVNC were diluted 500 times (v:v) in 
ultrapure water to determine the particle size and 
polydispersity, and in 10 mM sodium chloride for the 
determination of zeta potential. The analyses were 
performed in triplicate.  
Sample preparation  
Samples were diluted in acetonitrile and subsequently 
placed in vortex and ultrasound for pre-determined times. 
Subsequently, the samples underwent filtration by a 
polyacetilamide membrane with a porosity of 0.45 µm 
(Millipore).  
Spectrophotometric parameters  
The conditions of the spectrophotometric method were 
optimized for the determination of suspensions of SIVNC 
using UV-VIS spectrophotometer 1650 PC (Shimadzu) and 
are described in Table 2.  
Table 2. Spectrophotometric conditions applied in the 
determination of the suspension of simvastatin nanocapsules 
Parameter Description 
Wavelength 239 nm 
Scan peed medium 
Type derivative 
Order 2nd derivative 
Δλ 20,000 
Scale factor 9 
 
Validation of the analytical method  
Validation of the analytical method was performed 
following the criteria proposed by ANVISA 2017 and the 
International Council on Harmonization (ICH) 2005 (14, 
15). The parameters evaluated in the development of this 
work were specificity, linearity, intermediate precision, 
repeatability, robustness and accuracy. 
The specificity of the method was evaluated through the 
analysis of BLNC samples compared to the suspensions 
containing the SIVNC at the concentration of 30 µg/ml.  
The solutions of SIVNC and also the BLNC were compared 
according to the spectrum profile obtained by 
spectrophotometry zero, first and second order. The 
evaluation of the spectrophotometric profiles of distinctive 
orders of differentiation, as well as the scale factor and the 
Δλ,  allowed to limit the annulations point of BLNC and 
thus to determine the best wavelength for analysis.  
To test the linearity of the method, a stock solution of 1 
mg/ml simvastatin in acetonitrile was used. Subsequent 
dilutions to 20, 25, 30, 35, and 40 µg/ml were prepared with 
the same solvent in triplicate for the development of the 
analytical curve. The results were statistically evaluated 
through the analysis of variance (ANOVA) by 
GraphPadPrism software version 4.0.  
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Accuracy was assessed by analyzing nine sample solutions 
of SIVNC at concentrations of 20, 30 and 40 µg/ml in one 
day (repeatability) and through the intermediate precision 
with analysis in different days and by different analysts. The 
respose evaluated was the relative standard deviation (RSD).  
To determine the robustness of the method three parameters 
were assessed in different combinations: sonication time, 
wavelength and the presence or absence of filtration (Table 
3). The experiment followed an experimental design 23. 
Subsequently, the results were subjected to Student's t-test 
performed by GraphPadPrism version 4.0 software and 
plotted graphically using the Statistics software version 6.0.  
 
Table 3. Combination of parameters changed for robustness 
assessment. 
Sample λ (nm)a Sonication Filterb 
A1 237 28 Y 
A2 237 32 Y 
A3 237 28 N 
A4 237 32 N 
A5 241 28 Y 
A6 241 32 Y 
A7 241 28 N 
A8 241 32 N 
a λ: wavelength; bY: yes, N: no 
 
Accuracy of the method was determined following the 
principle of recovery. Fixed amounts of SIVNC sample (20 
µg/ml) were added to different concentrations of raw 
material (10, 15 and 20 µg/ml), resulting in concentrations 
of 30; 35 and 40 µg/ml of simvastatin. 
Comparison of analytical methods  
The values of simvastatin amount in the SIVNC at the 
accuracy evaluation were compared to those found with 
HPLC assay (12), based on Student's t-test, analyzed by 
GraphPadPrism software version 4.0, to justify the 
interchangeability of the methods.   
Results and discussion  
Development and characterization of nanocapsules  
The suspension containing SIVNC was developed by 
Lorenzoni et al. (2019) applying the API as characterized 
chemical standard. To prove the high purity of the 
simvastatin API, it was evaluated through infrared 
spectroscopy with Fourier transform, differential scanning 
calorimetry and X-ray diffraction, classifying the drug as 
adequate to the intended application (12), as required in the 
current Pharmacopoeia.  
The nanoencapsulated drug undergone characterization tests 
that were able to evaluate its stability and ensure that it is 
suspended on a nano scale. The physical-chemical 
characteristics of the suspensions of SIVNC and BLNC are 
described in Table 4.  
 
Table 4. Phisical-chemical properties of the suspentions of 
nanocapsules of simvastatin (SIVNC) and blank (BLNC). 
 






SIVNC 190.76 ± 1.98 0.098 ± 0.024 -17.4 ± 1.73 
BLNC 213.66 ± 1.15 0.111 ± 0.012 -20.4 ± 0.90 
*Mean value ± standard deviation (n=3) 
The zeta potential of a particle may be positive or negative 
depending on the nature of the polymer or material used to 
modify the surface (14). The values found are in agreement 
with the literature, considering that the negative charges are 
described for polymer suspensions. Experiments with 
poly(ε-caprolactone) nanocapsules containing diclofenac 
(17) and another containing indomethacin (18) showed 
negative zeta potential due to the presence of ester groups in 
the chemical structure of the polymer. When working with 
nanoscale formulations particles are ideally presented as 
monodispersion, with a polydispersity index of less than 0.2 
and an average particle diameter of no more than 300 
nanometers (19). Therefore, the results are within the 
requirements, considering the suspension of SIVNC stable 
and with nanometric particles.  
Development and validation of the analytical method  
To ensure that a new analytical method presents reliable 
information, it must be validated through a continuous 
process in which there is a schedule of the analytic strategy 
carried out through its development (20).  The validation 
must guarantee, through experimental studies, that the 
method meets the requirements of analytical applications, 
ensuring the reliability and conformity of the results (14).  
Regarding SIVNC, the conventional spectrophotometric 
method was replaced by the use of derivative 
spectrophotometry due to observation of great interference 
bulk material on the analysis (Figure 2), the BLNC 
suspension showed high absorbance at the wavelength 
indicated by the official compendia 238 nm, equivalent to 
21.13% of the total absorbance (21).  
 
Figure 2. Conventional spectrophotometry - 238 nm wavelength - 
concentration: 30 µg/ml; (a) BLNC (b) Simvastatin (c) SIVNC. 
 
According to Pascoal et al. (2003), one of the main problems 
of spectrophotometry in the regions of the ultraviolet/visible 
is associated with the overlapping of bands, which is the 
overrun of the electronic transitions or the charge transfer in 
the same solvent (23). To circumvent the problem of 
overlapping spectra, the derivative spectrophotometry 
conquered its space, with higher sensitivity and selectivity 
compared to conventional spectrophotometry, given by the 
separation of overlapping bands and due to the amplification 
of the derivative signal and the noise reduction (21). 
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Parameters were established for the elimination of the 
intervention of BLNC signals to the spectral resolution. 
Based on the concept that the superposition of the spectra of 
the components of a mixture can better individualize the 
constituents and eliminate the interference of one 
component over the other through the derivatization (20) it 
was set the need for spectrum transformation from the zero 
order to the derivative (Figure 3).  
The derivative spectrophotometry is the transformation of a 
usual spectrum through derivation, these spectra are 
obtained using information from the classical zero-order 
spectrum. Therefore, the derivation does not increase the 
amount of information, but it better individualizes the 
constituents by increasing the number of absorption bands 
and eliminating the large ones, improving the selectivity of 
small spectral features (22-24).  
 
Figure 3. 2nd order derivative - concentration: 30 µg/ml; (a) 
BLNC; (b) Simvastatin (c) SIVNC. 
 
Several techniques for the determination of drugs associated 
through derivative spectra are found in the scientific 
literature. The method chosen was the technique of 
cancellation point, also called zero-crossing, that measures 
the absolute absorption value of one component of the 
mixture in wavelength of the cancellation point (region 
which the absorbance of the interference equals to zero), 
reducing the systematic error when compared to the 
graphical determination (25, 26). In Figure 3 it is possible 
the perception of a cancelation point for the BLNC at 239 
nm, therefore this was the wavelength chosen for the 
photometric reading of the samples. Figure 3 represents a 
second order derivative spectrum, where the lambda delta 
(Δλ) is equal to 20,000 and the scale factor applied is 9. The 
choice of these parameters is directly related to the spectrum 
of zero order, a situation in which the derivative, the scan 
rate, the increment of Δλ (that the derivative is obtained) and 
the scaling factor are the main instrumental parameters that 
affect the derivative spectrum.  
The increase of the derivative order leads to a higher 
spectral resolution, the second order was chosen due to the 
existence of a cancellation point for the BLNC, whereas this 
point was nonexistent for the first order spectrum. The mean 
scanning speed is usually applied, since the slow increases 
the noise and the fast results in loss of resolution. The 
variation Δλ is the main instrumental parameter that affects 
the shape of the derivative spectrum, the value of 20,000 
was established due to the noise decrease when ranged from 
10,000 to 20,000 and higher values of Δλ can lead to a poor 
spectral resolution.  
The scale factor changes the wave amplitude and should be 
evaluated to avoid distorting the spectrum. It is capable of 
increasing the signal of the sample through the zero-order 
spectrum and therefore, the use of samples with high 
concentrations is not required, the response is increased by 
increasing the scale factor. This parameter was increased 
from 1 to 12, but factor 9 was chosen due to the presence of 
equal absorbance between the sample and standard, and to a 
BLNC absorption equal to zero, all on the same wavelength.  
The equation y = -0.002 x - 0.001 was obtained by the 
studies of the linear regression between the concentration of 
simvastatin and their responses, yielding a coefficient of 
determination of 0.992. Therefore the linearity curve can be 
used to quantify the experimental values of simvastatin in 
SIVNC. ANOVA demonstrated significant linear regression 
(p<0.05) and no significant linearity deviation (p>0.0d).  
Precision (repeatability) and intermediate precision results 
were expressed as RSD. These values are shown in Table 5.  












20 102.5 105.0 97.5 
30 103.3 105.0 101.7 
40 105.0 105.0 101.2 
Mean (%) 103.6 105.0 100.1 
RSD (%) 1.2 0.0 2.3 
 Intermediate precision 
Mean (%)  102.9  
RSD (%)  2.4  
aAnalyst 1; bAnalyst 2 
 
In table 5 it can be seen that the results presented 
satisfactory levels of RSD, all bellow the maximum 
acceptable value recommended by ANVISA, 5%, 
demonstrating the closeness of the results obtained with 
SIVNC samples and with different analysts. Therefore, the 
method developed has adequate repeatability and precision. 
The results of simvastatin content found in the accuracy test 
were compared to the results for method precision in the 
manuscript of Lorenzoni in 2019, where SIVNC suspension 
was subjected to HPLC method validation (12), the 
evaluation of these values was performed using the ANOVA 
test. The result was satisfactory, showing that the use of 
derivative spectrophotometry is an alternative to HPLC as 
there was no significant difference between the tests 
undertaken by each technique.  
Robustness is the ability of the method to not be affected by 
subtle irregularities (27). Based on the Student t-test, 
satisfactory results were found, showing no significant 
effects for the changes performed in sonication time and λ, 
but the use of filter demonstrated to be significant for the 
analysis of SIVNC (Fig. 4).  
  




Figure 4. Evaluation of the content as a function of λ variation and 
sonication time: (a) Samples with filter; (b) Samples without 
filtration.  
 
It is notable that the samples subjected to filtration showed 
lower levels compared to samples without filtration. 
Aperantlly, the filter would be retaining the drug, however, 
the BLNC has a known interference in the simvastatin UV 
signal, therefor the filter would be retaining the vehicle and 
the lower values are justified. The method presented to be 
robust for the changes in sonication time and λ. On the other 
hand, the filtration process demonstrated to be critical for 
the analysis, since it will prevent a higher absorption of the 
excipients.  
The accuracy of an analytical method is the closeness of the 
results obtained for the study in relation to the true value 
(14). The results for the accuracy of the method are shown 
in Table 6.  
 
Table 6. Recovery values for the developed method 
Simvastatin 
(µg/ml) 
Recovery (µg/ml) Amount (%) 
10 10.31 101.50 
15 15.27 100.22 
20 20.37 100.27 
Mean (%) 100.66 
RSD (%) 0.72 
 
 
The values reported in Table 6 were satisfactory since all 
recovery rates were between 100.27 and 101.50% 
demonstrating compliance with the limits established by the 
ICH, which are 98-102%. Therefore, the method can be 
considered accurate.   
Conclusion  
The analytical method applying derivative 
spectrophotometry for the detection and quantification of 
simvastatin in the suspension of SIVNC was developed and 
validated according to ANVISA (2017) and ICH (2005) 
specifications. It proved to be specific, linear, accurate, and 
robust regarding sonication time and λ. The robustness test 
demonstrated that filtration is a critical factor for the 
analysis of SIVNC. Thus, one can conclude that the 
derivative spectrophotometric method is a suitable 
alternative to the HPLC for the quantification of suspensions 
of SIVNC. 
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